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CERATOCONJUNTIVITE SEC A CANIN A
C arlos H orário  U G H T O W L E R 1; H ector Daniel H E R R E R A 2; Nelida V irginia G O M E Z '
SUMMARY
The authors make a description of the results attained with the topical use of keratoconjunctivitis 
sicca. In all treated cases they observed an increase in the values of the Schirmer tear test marked 
improvement of the eyes and furthermore an attenuation of the melanic pigment deposited on 
the cornea.
UNITERMS: Keratoconjunctivitis sicca; Cyclosporine; Dogs
INTRODUCTION
Canine KCS is a relatively frequent sickness and its therapeutic 
approach presents some difficulties, essentially fortwo reasons. 
These reasons are the impossibility in most cases of regaining 
an optimal lacrimal function and the problems which the 
dog’s owner must endure in order to efficiently substitute the 
lack of lacrimal fluid during the dog 's life.
The sickness will lead, in time, to blindness, due to corneal 
melanic pigm ent deposits and, in more severe cases, 
keratinization. In most cases, it will get to this point after 
having gone through a more or less long period of ocular 
irritation which is very troublesom for the patient and owner. 
This situation is aggravated by the fact that, with a very high 
frequency, this pathology is mistaken with a non-specific 
conjunctivitis and treated, thus leading to therapeutic failure 
and to the owner’s dismay.
Recent evidences lead to the probable existence o f an 
immunological etiology in most cases of dry eye l-4-5'6-7. This 
w ould po in t out to the co n v en ien ce  o f  em ploy ing  
immunosuppresive agents, such as cyclosporine A, as a 
therapeutic mean.
This would be done having in mind the possibility of arresting 
the immunological process, restoring the functionality of the 
lacrimal glands, healing the corneoconjunctival lesions and 
installing a less intensive therapy (less frequent medication), 
which will imply a lesser burden for the dog’s owner.
Accordingly to the above mentioned, we started this therapeutic 
trial, in order to evaluate the use of cyclosporine A in oily 
solution, in dogs with KCS. The objective of this work is to 
show the results obtained in the treatment of 15 clinical cases 
of KCS.
MATERIAL AND METHOD
Fifteen dogs were chosen. Its description can be seen in Tab.
I. The inclusion criterion in the present protocol was the 
previous existence of a chronic corneconjunctival process, 
with an evolution period ranging between 1 and 15 months, 
registered through anamnesis and by ophthalmological 
interview.
Most of the cases had presented during that period, as 
described by the dog’s owner, different degrees and types of 
secretion (mucous to purulent). Prescribed medications had 
been generally non-specific, such as antibiotics, ocular 
cicatrizants and antiinflammatories. Until these animals were 
included in the present study, none of them had a diagnosis of 
KCS and, therefore, had been devoid of specific treatment.
KCS was diagnosed based on the presence of characteristic 
clinical signs and the evaluation of lacrimal production 
through the Schirmer’s Test. The following scale was used =
> 10 mm/minute : NORMAL
5 to 10 mm/minute : SUSPICIOUS
< 5 mm/minute : POSITIVE FOR KCS
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TABLB I
Summary of all patients included in the study and Schirmer's 
'lest values for both eyes in first and following interviews 
(days 14 y 30). Buenos Aires, 1991.
N° Breed Sex Age
(Y)
Schirm er T ear Test (m m /m in)
1M Interview Day 14 Day 30
R.H. L.H. R.E. L.E. R.H. L.H.
1 Peking* l 10 2 4 to 10 9 12
2 Coeker Amer M 3 3 I 7 12 13 15
3 PirineosSheepdog I- 5 1 3 3 9 7 10
4 Mongrel M 6 0 2 10 9 15 1 1
5 Mongrel 1 0 0 2 3 3 2
6 i in ker Amer. M 8 0 4 7 to 13 7
7 Corker Amer. VI 10 'V 3 7 5 12 1 1
X Corker Amer 1 4 0 0 3 r » -
9 Corker A met r' 0 2 5 9 * *
10 Corker Amer. F 5 4 2 12 11 15 13
1 1 Mongrel Vi 0 11 .T - 9 15
12 IJuisa Apso M 8
_____-------------
7 4 7 10 12
13 Lhasa Apso M 6 5 4 ! « 9 10 14
414 Pekin ges VI 9 0 0 3 2 5
15 English Cocker M 7 4 to <) 10 7 14
1 = Female L.E = Left eye
M = Male Y = year
R.li = Right eye * = no t cxamcd
It was also taken into account, the degree o f corneal 
vascularization, the amount of mucous secretion and the 
intensity of pigmentation at the moment of interview. All 15 
dogs were treated during the beginning period exclusively 
with a 2% oily Cyclosporine A solution, one drop 3 times 
daily. As control days, we established days 14 and 30 after the 
first interview. Routine ophthalmologic examination and 
Schirmer Tear Test were done on each clinical consultation.
Schirmer’s Tear Test values for both eyes for first and 
following days ( 14 and 30) were recorded as basic information 
in this first experience.
RESULTS
l ;rom the original 15 patientes included in this study, we were 
able to complete the follow up on day 30 in only 13, having 
lost contact with cases 8 and 9.
At the beginning of the experience, 1 I patients (73.33%) 
showed bilateral KCS. with mean secretion values, measured 
by Schirmer's Tear Test of 1.36 mm/min. for the right eye 
(ranging between 0 and 4 mm/min.). The other 4 patients 
showed positive values for unilateral KCS of the right eye.
with an average value of 2.5 mm/min. In three of these cases, 
the contralateral eye showed suspicious values (mean of 5.5 
mm/min. in cases 7, 12 and 15). The last of the 4 cases had 
normal value for the contralateral eye ( 11 mm/min.). Follow 
up of the KCS cases is shown in Tab. 2.
TABLE 2
Change in lacrimal secretion measured with Schirmer's Tear 
Test in KCS unilateral cases treated with cyclosporine A (4 
cases). Buenos Aires. 1991.
E FIRST CONTROL CONTROL
Y INTKRVIKW DAY 14 DAY .30
b
+ S N + s N * S N
R 4 - 1 .3 - 3 1
L - 3 1 - 1 .3 - - 4
R = Right S = Suspicious value for KCS
L = Left N = Normal values of lacrimal
+ = Positive value for KCS secretion
The data analyzed on day 14 displayed a significant variation 
in the values of the Schirmer's Tear Test which allowed for 
a recategorization of the patients within the scale of test.
In this opportunity, the 1 I cases of bilateral KCS showed an 
average increase of lacrimal secretion of 268.32% for both 
eyes. This means an initial average value of 1.816 mm/min. 
for both eyes vs. a value of 6.86 mm/min. on day 14, with a 
net increase in lacrimal production of 5.044 mm/min. For the 
right eyes, the initial average value of 1.36 mm/min. went up 
to 6 mm/min. (net increase of 4.64 mm/min.), which would 
result in an 341.18% increase. For the left eye, average values 
went up from 2.27 mm/min. to 6.73 mm/min.. with a net 
increase of 4.46 mm/min. (196.48%). Results are shown in 
Tab. 3.
TABLE 3
Change in lacrimal secretion measured with Schirmer's Tear 






Interview Control Day 14
Control Day 30
+ S No
+ S No - S No
N % N % N % N % N % N
R 9 . 3 33 4 44 2 22 1 1 1 3 33 5 55
L í 9 2 ■>■> 4 44 3 33 2 ■>■» 1 11 6 66
R = Right S = Suspicious value for KCS
L = Left No = Normal values o f lacrimal secretion
+ = Positive value for KCS N = Number o f cases
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One day 30, there was a marked increase in the trend shown 
in day 14 (Fig. 1). Over 9 cases, average values for the right 
eyes were 10 mm/min., with a net increase of 8.64 mm/min. 
(635.29% increase in relation to the initial value). For the left 
eyes, average value was 9.79 mm/min., with a net increase of 
7.51 mm/min. (330.84%).
The mean overall increase in global lacrimal secretion was 
483.07% (Tab. 4).
TABLE 4
Change in Schirmer's Tear Test values after 30 days of topical 
treatment with cyclosporine A in 9 patients with bilateral 
KCS. Buenos Aires, 1991.
EYES FIRST INTERVIEW CO NTROL DAY 14 CO NTROL DAY 30
MM/MIN. M M /M IN . * M M /M IN. *
RIGHT 1.23 4.64 (341.18% ) 8.64 (635.29% )
LEFT 2.27 4.46 (196.48% ) 7.51 (330.84% )
* Values given as net increase in lacrimal secretion
Of the group of patients under study, only 2 of them (13.33%) 
were found with abnormal results to the Schirmer’s Tear Test 
at the end of the experience to attain an average increase in 
lacrimal secretion of 3.5 mm/min. It is interesting to note that, 
at the beginning of treatment, these two patients showed zero 
results to the Schirmer’s Tear Test in both eyes. All of the 
other 13 patients (86.67%) reached normal average values for 
both eyes (10.64 mm/min. for the right eye and 12.45 mm/ 
min. for the left one) (Fig. 2).
This favorable evolution of the lacrimal secretion was 
accompanied by an improvement of the clinical appearance 
of the eyes (Fig. 1,2, 3 and 4). The typical mucous secretion 
of this sickness was notably reduced at the first control and 
completely disappeared by the time of the final control day. 
Also, the corneal vascularization showed by some of the 
patients at the first interview was reduced or disappeared, in 
correlation with the increase in lacrimal secretion. In some 
cases it was possible to observe a decrease in corneal 
pigmentation.
DISCUSSION
KCS is a sickness that presents two relevant treatment 
problems: one is lack of knowledge of its etiology and the 
other is high incidcnce of diagnostic error.
As to the etiology, bibliographical references of the last 3 
years suggest that a high percentage of KCS in dogs is 
Iriggered by an immunological reaction.
Recent research on experimental models show in lacrimal 
glands a change in the relationship between T  suppressor and 
T helper cells, with an increase of T helpers 3-5.
Cyclosporine A is a non cytotoxic immunosuppressor drug, 
used to reduce rejection in organ transplants4. Its main effect 
is inhibition of T helper cells, favoring thus the action of T 
suppressor cells. This effects leads the balance of the 
immunological regulation carried on by T cells, towards 
immunotolerance 2-3-4-6.
The use of cyclosporine A as a means to revert glandular 
adenitis was considered on the basis o f results from experi­
mental models and based on the hypothesis that canine KCS 
is produced by a deficiency in T suppressor cells activity 7.
CONCLUSIONS (see Fig. 3 ,4 , 5 and 6)
1. Every treated case showed an increase in lacrimal secretion, 
ranging from a minimum value of 3.5 mm/min. to a 
maximum of 12.45 mm/min.;
2. 86.67% of the patientes (13 out of 15) recovered normal 
values of lacrimal secretion;
3. Marked reduction, and in some cases, complete disappea­
rance of the mucous secretion typical of this sickness, 
were observed at the time of the first control (day 14);
4. Most of the treated eyes recovered their normal aspect and 
it was possible to observe partial or total remission of 
conjunctival vascularization and hyperemia;
5. Pigment mobilization was observed in some cases , with 
an improvement of the corneal transparency.
RESUMO
Realizou descrição dos resultados obtidos com o uso tópico da Cielosporina A em casos clínicos 
de ceratoconjuntivite seca em cães. Observam que em todos os casos tratados houve o aumento 
dos valores da prova de Schirmer, melhora marcada do estado clínico dos olhos e depositado 
sobre a córnea.
UNITERMOS: Ceratoconjuntivite seca; Ciclosporinas; Cães
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FIGURE 1
Improve of cases on day 14 and day 30 controls.
FIGURE 2
Values on lacrimal secretion on 1st interview and day 30 control before topical treatment with cyclosporine A.
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A
FIGURE 3
Case ne 11 - A - Day O. STT 0 mm/min.
B - Day 14. STT 7 mm/min.
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FIGURE 4
Case np 10 - A - Right eve: Day 0. STT 4 mm/min.
B - Left eye: Day 0. STT 2 mm/min.
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Case n9 10 - A - Right eye; Day 14, STT 12 mm/min.
B - Left eye; Day 14. STT 11 mm/min.
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B
FIGURE 6
Case n9 10 - A - Right eye; Day 50. See the pigment mobilization and corneal transparence. 
B - Left eye; Day 50.
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